Ocular involvement in coronavirus disease 2019 (COVID-19): a clinical and molecular analysis

Abstract

Purpose

Coronavirus disease 2019 (COVID-19) caused a global pandemic with millions infected worldwide. Little is known on the ocular involvement associated with the disease. The aim of this study was to assess the clinical and molecular ocular involvement among patients with confirmed COVID-19 admitted to a tertiary care facility.

Methods

Consecutive patients admitted to the COVID-19 Ward of the Shamir Medical Center in Israel during March and April, 2020 were included. The control group included patients negative for COVID-19 admitted during a similar period to a different ward. Patients were examined by trained Ophthalmologists. SARS-CoV-2 conjunctival swab samples were obtained.

Results

Included were 48 patients, 16 with confirmed COVID-19 and 32 controls. Median patient age was 68.5 (interquartile range: 31.5, mean: 63 ± 21) years and 48% were male. Active conjunctival injection was present in three patients (19%) with COVID-19, compared to none in the controls (p = 0.034). Patients with COVID-19 were more likely to complain of foreign body sensation (31.3% vs 3.1%, p = 0.005) and redness of the eye (25% vs 0%, p = 0.003). Conjunctival injection was associated with loss of smell and taste (75% vs 7.7%, p = 0.018). Viral conjunctival swab tests all showed negative results for all three viral genes tested (E, N, and RdRp).

Conclusions

Among patients admitted to a tertiary referral center with confirmed COVID-19, active conjunctival injection was noted in one out of five cases, and was associated with loss of smell and taste. Conjunctival swabs for viral RNA were negative in patients with and without ocular involvement.

Electronic supplementary material

The online version of this article (10.1007/s10792-020-01592-1) contains supplementary material, which is available to authorized users.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19) [1]. Since first identified in December 2019 at Wuhan, China, a global pandemic has emerged with almost 3,000,000 confirmed cases and over 200,000 deaths reported worldwide as for April 27, 2020 [2]. SARS­CoV-2 is predominantly transmitted when droplets from an infected person generate contact with mucous membranes of an uninfected individual. Currently, SARS-CoV-2 is diagnosed upon a reverse transcriptase–polymerase chain reaction (RT-PCR) assay from an oral or nasopharyngeal specimen [3].

Fever and cough are considered the hallmark of the disease. Other symptoms observed include weakness, diarrhea, sore throat and loss of smell and taste [4]. While the cumulative medical reports on the subject of COVID-19 are growing rapidly, studies examining the ocular involvement in this disease remain scarce [5–7]. Some evidence suggests that conjunctivitis could uncommonly be the first presenting symptom of COVID-19 and that ocular transmission might be an important route of transmission [8, 9]. Furthermore, previous research has described several ocular pathologies caused by other members of the coronaviruses family, including conjunctivitis, anterior and posterior uveitis, retinitis and optic nerve injury [10]. Given the close proximity between ophthalmologists and patients during examination, ophthalmologists are at increased risk of infection [11, 12].

This study aimed to evaluate the ocular manifestations in patients diagnosed with COVID-19. In addition, we aim to assess viral RNA presence from conjunctival swab samples.

Methods

This study adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board (IRB) of the Shamir Medical Center. All participants provided written informed consent prior to enrollment. No animal subjects were included in this study.

Patient population

The study group included consecutive patients admitted to the COVID-19 Ward of the Shamir Medical Center during 24/03/2020–25/04/2020 and that provided consent to participate in the study. Patients of any age were included and were required to have at least one positive SARS-CoV-2 PCR nasopharyngeal swab test.

The control group included consecutive patients admitted during a similar period to the Internal Medicine wards A, B and C of the Shamir Medical Center in a 1:2 ratio to cases. These wards admit patients who are not suspected of having COVID-19 or being carriers of SARS-CoV-2. Routine screening for patients and staff regularly occurs in these wards and all control patients were screened negative for SARS-CoV-2 at RT-PCR tests.

Clinical evaluation and sample acquisition

Included patients were questioned on systemic and ocular history, current symptoms and were examined by one of two trained Ophthalmologists (IH or AS). All included patients were questioned equally on their symptoms according to a predetermined questionnaire to avoid selection bias. To reduce the risk of cross contamination, the use of a slit lamp was avoided and patients were examined with a portable set of testing aids. SARS-CoV-2 conjunctival swab samples were obtained using the standard nasopharyngeal swab, gently scraped in the inferior ocular fornix. Supplemental Figure 1 illustrates the sample acquisition technique from a patient with COVID-19 (written consent was obtained from the patient for the publication of these images). No local anesthesia or any other local treatment was instilled to the eye prior to testing in order to maintain testing accuracy. Swabs were routinely obtained from the right eye, unless apparent unilateral conjunctivitis was present, in which case the affected eye was swabbed regardless of laterality. Bacterial culture swabs were obtained in a similar manner at least 1 h after the viral swab was taken. These were taken in order to assess the possible effect of viral involvement on normal ocular flora.

The main outcome measures were ocular involvement rates among patients with confirmed COVID-19, and the rate of positive viral conjunctival swab samples among patients with and without ocular involvement. Conjunctival injection was defined as symptomatic conjunctival hyperemia involving the fornices and palpebral conjunctiva. Conjunctival injection was graded on a scale of 0–4 (0—none, 1—mild, 2—mild to moderate, 3—moderate, and 4—severe). Secondary outcomes included association of ocular manifestations with blood testing results, vital signs and systemic manifestations.

COVID-19 patients were clinically categorized to mild, moderate or severe on a daily basis according to a risk assessment calculated using the Modified Early Warning Score (MEWS) [13]. Clinical variables were recorded including presenting symptoms, vital signs, laboratory results and risk assessment according to the MEWS.

Laboratory procedures

Eleven out of 16 patients with confirmed COVID-19 had ocular samples taken for SARS-CoV-2. Three patients had bacterial conjunctival swab samples taken. Samples were tested for SARS-CoV-2 using reverse-transcription polymerase chain reaction (RT-PCR) analysis that target the E, N, and RdRp RNA-dependent RNA polymerase genes. Oropharyngeal samples were taken as part of routine clinical care while ocular samples were taken for research purposes only. Both were tested in a clinical diagnostic laboratory at Shamir Medical Center using similar methods.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics 25 (IBM Corp. Armonk, NY). Data are presented as mean ± standard deviation (SD) unless otherwise specified. Categorical variables were compared using the chi-square or Fisher’s Exact test, as appropriate. Clinical parameters distributions were tested for normality by the Shapiro–Wilk test. Independent and paired T tests were conducted for continuous variables with a normal distribution and Wilcoxon signed–rank test and the Mann–Whitney-U test for variables with a non-normal distribution. p values less than 0.05 on a two-sided test were considered statistically significant.

Results

Included were 48 patients, 16 with confirmed COVID-19 and 32 controls who were negative for COVID-19. Baseline medical and ocular history, as well as baseline vital signs, laboratory results, symptoms and epidemiological background are detailed in Tables 1 and 2.

Table 1.

Baseline patient characteristics

Variable	COVID-19 patients	Controls	p value
	n = 16	n = 32
Age (years)	58.7 (24)	65.7 (19)	0.286
Male gender	7 (43.7)	16 (50.0)	0.683
Medical history
Asthma	1 (6.3)	1 (3.1)	0.610
Smoker	5 (31.3)	15 (46.9)	0.301
COPD	1 (6.3)	5 (15.6)	0.355
Chronic kidney disease	1 (6.3)	11 (34.4)	0.034
Chronic dialysis	1 (6.3)	2 (6.3)	0.746
Obstructive sleep apnea	0 (0)	1 (3.1)	0.475
Stroke	2 (13.3)	NA	–
Heart failure	2 (12.5)	4 (12.5)	0.688
Diabetes mellitus	6 (37.5)	13 (40.6)	0.835
Essential hypertension	7 (43.8)	21 (65.6)	0.147
Ocular historya
Glaucoma	1 (6.3)	4 (12.5)	0.504
Dry-eye disease	0 (0)	2 (6.2)	0.307
Status post cataract surgery	1 (6.3)	10 (31)	0.052
Status post vitrectomy	1 (6.3)	1 (3.1)	0.610

Baseline patient characteristics of consecutive patients with confirmed COVID-19 and patients not suspected of having COVID-19 admitted to Shamir medical center during March and April 2020. Values are presented as mean (standard deviation) for continuous variable and as number (percent) for categorical variables. COVID-19, Coronavirus disease 2019. COPD, chronic obstructive pulmonary disease

^aIn one or both eyes

Table 2.

Clinical and laboratory data of the study groups at presentation

Variable	COVID-19 patients	Controls	Reference range	p value
	n = 16	n = 32
Epidimiological background
Recent travel abroad	1 (6.2)	0 (0)		0.153
Known COVID-19 contacts	10 (63)	0 (0)		< 0.001
Symptoms
Cough	11 (69)	3 (9.4)		< 0.001
Shotness of breath	7 (44)	11 (34.4)		0.527
Diarrhea	2 (13)	2 (6.3)		0.460
Sore throat	3 (19)	2 (6.3)		0.181
Hyposmia	3 (19)	0 (0)		0.011
Dysgeusia	3 (19)	0 (0)		0.011
Vital signs
Temperature > 38.0 °C	9 (56)	5 (15.6)		0.004
Heart rate > 100 beats per min	1 (6)	5 (15.6)		0.355
Saturation < 96% at room air	5 (31)	8 (25)		0.646
Laboratory results
Hemoglobin (mg/dL)	12.7 (2.2)	11.4 (2.67)	13.5–17.5	0.113
White blood count (cells per µL)	6.1 (2.3)	7.4 (4.7)	4.0–11.0	0.117
Neutrophiles count (cells per µL)	4.4 (1.9)	6.2 (4.5)	2.0–7.7	0.145
Lymphocytes count (cells per µL)	1.5 (0.6)	1.4 (0.8)	1.0–4.0	0.608
Platlets (cells per µL)	220 (63)	237 (114)	150–450	0.298
Creatinine (mg/dL)	0.82 (0.22)	1.04 (1.03)	0.7–1.20	0.126
Alanine aminotransferase > 40 U/liter	0 (0)	9 (28.1)		0.019
Aspartate aminotransferase > 40 U/liter	1 (6.3)	8 (25)		0.117
Lactate dehydrogenase (mg/dL)	460 (125.8)	488 (360.9)	240–480	0.290
C-reactive protein (mg/L)	18 (74.6)	22.9 (58.8)	0.3–5.00	0.923
Pathological electrocardiogram	2 (12.5)	9 (33)		0.130
Pathological chest X ray	3 (18.8)	13 (46)		0.066

Epidemiological, clinical and laboratory data of consecutive patients with confirmed COVID-19 and patients not suspected of having COVID-19 admitted to Shamir medical center during March and April 2020. Values are presented as mean (standard deviation) for continuous variable and as number (percent) for categorical variables. COVID-19, Coronavirus disease 2019

Active ocular involvement

Active conjunctival injection was present in three patients with COVID-19 (19%, 3/16), all but one with bilateral presentation. Ocular discharge was present in one of the cases, as further detailed below. All three patients complained of irritation, foreign body sensation and redness. Follicular reaction was seen in one of the patients. Among the control group no patients were documented as having active conjunctival injection (19% vs 0%, p = 0.034) and none had discharge (6% vs 0%, p = 0.721). Compared with the controls, a higher percentage of patients with COVID-19 reported a foreign body sensation (31.3% vs 3.1%, p = 0.005), redness of the eye (25% vs 0%, p = 0.003), and any redness or discharge in the 30 days prior to admission (31.3% vs 0%, p = 0.001). Ocular exam findings and symptoms are further detailed in Table 3.

Table 3.

Ocular signs and symptoms

Variable	COVID-19 patients	Controls	p value
	n = 16	n = 32
Ocular symptoms
Irritationa	5 (31.3)	4 (12.5)	0.121
Foreign body sensationa	5 (31.3)	1 (3.1)	0.005
Dischargea	1 (6.3)	0 (0)	0.153
Red eyea	4 (25)	0 (0)	0.003
Prior conjunctivitis b	5 (31.3)	0 (0)	0.001
Ocular examination findings
Conjunctival injection ≥ + 2c	3 (19)	0 (0)	0.034
Discharge ≥ + 1c	1 (6.2)	0 (0)	0.153
Eyelid erythema ≥ + 1c	1 (6.2)	0 (0)	0.153

Ocular signs and symptoms of consecutive patients with confirmed COVID-19 and patients not suspected of having COVID-19 admitted to Shamir medical center during March and April 2020. Values are presented as mean (standard deviation) for continuous variable and as number (percent) for categorical variables. COVID-19, Coronavirus disease 2019

^aAs reported by the patient on a scale of 0–10

^bAny redness or discharge in the 30 days prior to admission

^cAs assessed by the examining ophthalmologist between 0 and 4

Among patients with COVID-19, active conjunctival injection was associated with loss of smell and loss of taste as part of the clinical presentation (66.7% vs 7.7%, p = 0.018). A non-significant trend existed for association with a more severe disease course, as these patients had a higher MEWS at admission (median: 2 vs 1; mean: 3.7 ± 3.9 vs 2.7 ± 1.8, p = 0.402), lower blood oxygen saturation at admission (median: 98.0% vs 99.0%; mean: 95.3 ± 5.5% vs 96.5 ± 4.2%, p = 0.433), lower systolic blood pressure (median: 123 mmHg vs 139 mmHg; mean: 119 ± 6.2 mmHg vs 139 ± 22 mmHg, p = 0.193), higher heart rate (median: 89 BPM vs 80 BPM; mean: 96 ± 22 BPM vs 80 ± 10 BPM, p = 0.033), higher temperature (median: 37.0 °C vs 36.7 °C; mean: 37.2 ± 0.4 °C vs 36.8 ± 0.5 °C, p = 0.474) and higher white blood cell count (median: 9.0 cells per µL vs 7.0 cells per µL; mean: 7.6 ± 2.3 cells per µL vs 6.1 ± 2.8 cells per µL, p = 0.327).

Microbiological outcomes

Conjunctival swab testing for viral RNA were taken from 11 patients, including one of the three patients with diagnosed active conjunctival injection. All showed negative results for all three genes tested (E gene, N gene, and RdRp gene). Bacterial conjunctival swab samples revealed growth of Staphylococcus epidermidis in one case and had no growth in two other cases.

COVID-19 patients with active conjunctival injection: case summaries

Patient #1 was an 86-year-old female who presented with fever, cough and shortness of breath 1 week prior to her admission and was tested positive for COVID-19. She was a known smoker, had asthma and ischemic heart disease. She was pseudophakic in both eyes. On admission she had low blood oxygen saturation (90%) and was categorized as severe COVID-19 (MEWS of 9). She was started on oxygen by face mask, Hydroxychloroquine 200 mg twice a day and received several doses of Tocilizumab. Two days after admission she complained of discharge from her left eye. On exam there was active conjunctival injection graded + 3 in the left eye only with follicular reaction, associated with discharge graded + 1. She was started on antibiotic ointment with improvement. SARS-CoV-2 conjunctival swab was negative for viral RNA and bacterial culture results were positive for Staphylococcus epidermidis growth.

Patient #2 was a 48-year-old male who presented with a 1-day history of shortness of breath and noted loss of smell and taste. He was otherwise healthy and had no ocular history. On his admission was categorized as mild (MEWS of 0). When actively questioned he reported irritation, redness and foreign body sensation in both eyes in the past 2 days. On exam there was active conjunctival injection graded + 2 in both eyes with a + 1 watery discharge. He declined any conjunctival swabs from being taken.

Patient #3 was a 22-year-old male who presented with a 3-day history of sore throat loss of smell and loss of taste. He was a smoker and had no ocular history. Upon admission he was categorized as mild (MEWS of 2). When actively questioned he reported on irritation and redness in both eyes for the last week. On exam there was active conjunctival injection graded + 2 in both eyes with no discharge. He declined any conjunctival swabs from being taken.

Discussion

In this study, we evaluated the ocular signs and symptoms, as well as the presence of SARS-CoV-2 in conjunctival swab samples among patients with COVID-19 in one tertiary referral center during March and April of 2020. Outcomes were compared to a control group of patients negative for COVID-19, admitted during a similar period to a different ward. The results show that active conjunctival injection was present in 19% of cases and was associated with loss of smell and taste as part of the clinical presentation. Patients with COVID-19 were also more likely to complain of foreign body sensation and redness of the eye compared to patients negative for COVID-19. Conjunctival swabs for viral RNA were negative in patients with and without ocular involvement.

To date, little is known regarding the presence of SARS-CoV-2 on the ocular surface. Currently there are limited studies that report on the subject, all from East Asia [5, 7, 14, 15]. Reported positive conjunctival swab rates were between 0 and 5%. Furthermore, a recent meta-analysis reported that the pooled sensitivity of ocular tissue and fluid in detecting SARS-CoV-2 was only 0.6% in comparison with nasopharyngeal and sputum swabs [16]. It is interesting to note the recent publication by Seah et al. who examined 64 samples from 17 patients using a Schirmer test strip. They reported all examinations negative for viral RNA [17]. Our sampling technique was different. While Shea et al. focused on the existence of viral load in the tears, the method we employed benefits from direct scraping of conjunctival cells. The similarity in results however is consistent with the presumption of a low viral load in this tissue.

In our study none of the conjunctival swab samples were positive for SARS-CoV-2. This result could have been influenced by the limited sensitivity of the test, which was not designed or validated for conjunctival sampling, but rather for oropharyngeal testing. Another interesting possibility however relates to the limited viral load present in the conjunctiva. This possibility could have implications on the infectious capacity of this tissue. Some evidence suggests that droplets expelled from the mouth or nose of a patient can come in contact with an examiner’s eyes, forming an avenue of infection [8]. However the authors could find no evidence of infection originating from conjunctival tissue of an infected patient. Which appears in agreement with our results here. This could be an encouraging fact for ophthalmologists, who should nevertheless be highly protected due to the close proximity to patients during examination.

Active conjunctival involvement was associated with loss of smell and taste as part of the clinical presentation and a trend existed for a more severe disease course. Loss of smell or taste was a relatively late symptom to be revealed as associated with the disease. Little is currently known on the pathophysiologic mechanism by which it develops [18, 19]. We theorize that ocular involvement was associated with increased viral load in the nasal cavity and could perhaps have led to this association.

Previous studies have also suggested that ocular involvement is associated with a more severe disease presentation [5]. Several clinical measures related to disease severity were more pronounced among patients with ocular involvement in our study group. However, these did not reach statistical significance. The inability to reach statistical significance might be related to our exclusion of highly severe cases on account of their inability to provide consent to participate in the study. In addition, the relatively young patient age seen in our patient group (59 ± 24 years), might also have inadvertently excluded more severe cases. Patient’s mean age might have been influenced by the lesser ability of older patients to provide consent given the more severe manifestations of the disease at older ages. More data is needed, however conjunctival involvement should prompt the treating physicians to carefully monitor and evaluate the patient for other markers of disease severity.

It is interesting to note that ocular involvement was seen as a late presentation in patient #1, with ocular symptoms appearing at 9 days (after the onset of respiratory symptoms and 2 days into her admission), while in patients #2 and #3 ocular symptoms preceded respiratory ones. In patient #2 they occurred 1 day prior to respiratory symptoms onset (which coincided with loss of smell and taste) and in patient #3, 4 days prior to respiratory symptoms onset (sore throat and loss of smell and of taste). It should also be noted that when COVID-19 patients were questioned on redness or discharge in the 30 days prior to admission, five (Patients #2, #3 and three additional patients) responded positively (compared to none in the control group, p = 0.001, Table 3). A review of their charts reveals that the three additional patients had respiratory symptoms well before admission to our medical facility. This might suggest that these three patients with COVID-19 could have had ocular involvement at early stages as well. However due to the fact that these resolved, and could not be verified in clinical examination, they were excluded from the primary analysis.

In April of 2020 Neri and Pichi [20] suggested that an animal model where murine coronavirus induced an acute and long-lasting disease of the retina might serve as a model to examine COVID-19 associated inflammatory reaction. This model termed experimental coronavirus retinopathy (ECOR), suggests that SARS-COV-2 could have tropism for ocular tissues and induce a primary infection triggering the immune system, followed by a second autoimmune stage in which postviral inflammation can develop. Although in the ECOR model, using murine coronavirus, specific retinotropism was seen, humans affected by SARS-COV-2 might react differently, in ways also affecting the ocular surface. It would be interesting to follow the long-term retinal involvement of patients affected by COVID-19-associated conjunctivitis.

This study has several limitations. First, to reduce the risk of cross contamination of equipment, the use of a slit-lamp was avoided, as was indirect ophthalmoscopy. We therefore cannot comment on the rates of anterior or posterior uveitis as well as retinal pathologies. Second, patients with a highly severe course of disease were inherently excluded as they were unable to provide consent. Third, ocular sampling for SARS-CoV-2 among patients with active conjunctival injection were available in only one patient. Finally, this study included a relatively small sample size. The strengths of this study include the combination of clinical and molecular analysis and the use of an independent control group, as well as the assessment of a patient population outside of East Asia.

To conclude, among patients admitted to a tertiary referral center with confirmed COVID-19, active conjunctival injection was present in 19% of cases and was associated with loss of smell and taste as part of the clinical presentation. Patients with COVID-19 were also more likely to complain of foreign body sensation and redness of the eye compared to those negative for COVID-19. Conjunctival swabs for viral RNA were negative in patients with and without ocular involvement. These results could have implications on screening and triage of patients affected by COVID-19 as well as on implementation of appropriate protective measures for ophthalmology staff treating affected patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Funding

None.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.